카리즈라이프사이언스(CAI) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 카리즈라이프사이언스(CAI)?

카리즈라이프사이언스(CAI) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of CAI?

The market cap of CAI is approximately $4.4B, ranking 1,496 within its sector.

Q: What is the 52-week high and low for CAI?

CAI has recorded a 52-week high of $42.50 and a low of $14.19.

CAI

Caris Life Sciences Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$15.63

+0.11 ▲ +0.71%

🌙 7월 27일 5:32 PM ET (한국 7/28 06:32)

$15.70

+0.07 ▲ +0.45%

카리즈라이프사이언스(CAI) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$4.4B

스몰캡

P/E

배당수익률

없음

52주 위치

저점 +10% · 고점 -63%

애널리스트

매수

Fundamental health

vs. Biotechnology 중형주

수익성

Top 28%

성장

Top 18%

밸류에이션

Top 47%

재무 안정

Top 40%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-1.47	Insider Own ⓘ	56.72%	Shs Outstand ⓘ	282.6M	Perf Week ⓘ	0.45%
Market Cap ⓘ	4.42B	Forward P/E ⓘ	44.84	EPS next Y ⓘ	178.27%	Insider Trans ⓘ	0.06%	Shs Float ⓘ	122.3M	Perf Month ⓘ	-16.42%
Enterprise Value ⓘ	4.03B	PEG ⓘ	-	EPS next Q ⓘ	0.01	Inst Own ⓘ	48.29%	Short Float ⓘ	9.59%	Perf Quarter ⓘ	-22.62%
Income ⓘ	-0.41B	P/S ⓘ	4.87	EPS this Y ⓘ	130.76%	Inst Trans ⓘ	16.99%	Short Ratio ⓘ	3.78	Perf Half Y ⓘ	-37.48%
Sales ⓘ	0.91B	P/B ⓘ	7.44	EPS next 5Y ⓘ	-	ROA ⓘ	4.67%	Short Interest ⓘ	11.73M	Perf YTD ⓘ	-42.07%
Book/sh ⓘ	2.1	P/C ⓘ	5.37	EPS past 3/5Y ⓘ	-7.57% -	ROE ⓘ	28.35%	52W High ⓘ	-63.22% ($42.50)	Perf Year ⓘ	-47.09%
Cash/sh ⓘ	2.91	P/FCF ⓘ	38.17	Sales past 3/5Y ⓘ	62.87% -	ROIC ⓘ	3.34%	52W Low ⓘ	10.15% ($14.19)	Perf 3Y ⓘ	-
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	31.21	EPS Y/Y TTM ⓘ	-10.99%	Gross Margin ⓘ	68.72%	Volatility(W/M) ⓘ	5.65% 6.49%	Perf 5Y ⓘ	-
Dividend TTM ⓘ	-	EV/Sales ⓘ	4.44	Sales Y/Y TTM ⓘ	100.51%	Oper. Margin ⓘ	11.94%	ATR (14) ⓘ	0.99	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	6.52	EPS Q/Q ⓘ	99.6%	Profit Margin ⓘ	-45.35%	RSI (14) ⓘ	39.42	Recom ⓘ	1.54
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	7.05	Sales Q/Q ⓘ	78.78%	SMA20 ⓘ	-7.67% ($16.93)	Beta ⓘ	0.73	Target Price ⓘ	$27
Payout ⓘ	-	Debt/Eq ⓘ	0.73	Earnings ⓘ	2026/8/5	SMA50 ⓘ	-7.09% ($16.82)	Rel Volume ⓘ	1.11	Prev Close ⓘ	$15.52
Employees ⓘ	1846	LT Debt/Eq ⓘ	0.72	EPS/Sales Surpr. ⓘ	100% 3.23%	SMA200 ⓘ	-28.82% ($21.96)	Avg Volume(3M) ⓘ	3.10M	Price ⓘ	$15.63
IPO ⓘ	2025/6/18	Option/Short ⓘ	Yes/Yes			Trades ⓘ	27006	Volume ⓘ	3,453,448	Change ⓘ	0.71%

Quarterly earnings trend SEC filings · USD

24.6

24.9

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $216M (YoY +79%) · 순이익 $-1M (YoY +100%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Caris Life Sciences Inc (CAI) Investment Analysis

What kind of company is Caris Life Sciences Inc?

카리즈라이프사이언스(CAI) 방어주

Healthcare · Biotechnology

#1496 by Market Cap — Mid-Cap

🧬 An AI-powered diagnostics company specializing in cancer molecular diagnostics and precision medicine. It supports personalized treatment for cancer patients through whole-genome and whole-transcriptome sequencing that analyzes tumor tissue and blood, and is rapidly growing in the field of precision oncology based on its extensive molecular database. Its core business is molecular profiling services.

Learn more about Caris Life Sciences Inc →

Market Cap

$4.4B

Approx. KRW 6.1 trillion

⚖️ 2% of Samsung Electronics

Market Cap Rank1496

Employees1,846people

IPO2025/06/18

Current Price$15.63 ≈ 21,413원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-9

8월 5일 (수) · 장 마감 후

예상 EPS $0.01

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후 EPS +100.0% 매출 +3.2%

🔔 Earnings release 2026년 2월 26일 (목) · 장 마감 후 EPS +477.3% 매출 +21.8%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

11.9%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 중형주 Median -140.2% · Top 21%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

-45.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

68.7%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 중형주 Median 82.6% · Bottom 32%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

28.4%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 중형주 Median -17.0% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

4.7%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 중형주 Median -9.3% · Top 24%

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

3.3%

✓ 양호

My positionMid-range

Low range Average High range

Healthcare 중형주 Median -11.9% · Top 27%

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.73

✓ Average

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

7.05

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

6.52

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$27.00

현재가 대비 +72.7%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

44.84배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+178.3%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 2 of the last 2 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+134.3%

평균 서프라이즈

2026.05.07

상회

실적 $0.00 · 예상 $-0.02 +100.0%

2026.02.26

상회

실적 $0.28 · 예상 $0.10 +168.7%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth

Above the industry average, both historically and going forward

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+130.8%

우수

My positionTop 5%

Low range Average High range

방어주 중형주 Median 5.2% · Top tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+178.3%

우수

My positionTop 5%

Low range Average High range

방어주 중형주 Median 10.7% · Top tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

-7.6%

평균

My positionMid-range

Low range Average High range

방어주 중형주 Median 4.5% · Bottom 29%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+78.8%

우수

My positionTop 5%

Low range Average High range

방어주 중형주 Median 4.6% · Top tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Underperformed the market by 63%p over the past year

CAI -47.1% · S&P 500 +16.0%

Excess return vs. market (price-based, ex-dividends)

1-year basis

vs S&P 500

-63.1%p

Significantly behind the market

vs Health Care (XLV)

-66.8%p

Significantly behind the sector average

Rank among peers

1-year return Lowest among peers Based on 76 peers

Current position within 52-week range

Low (-10.2%p) High (-63.2%p)

Current price is 10.2% above the 52-week low and 63.2% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-34.8%

Annualized volatility

68.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $15.63 below the midline ($16.93). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.541 < Signal -0.349 in negative zone + Hist negative (-0.192). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 39.5 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 14.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Sales, Pricey on Vs. Earnings, In line with peers on Vs. Assets·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Mid-range

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

44.84x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 중형주 median 27.75x · Bottom 24% — expensive within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

7.44x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 중형주 median 6.81x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

4.87x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 중형주 median 23.18x · Top 12% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

31.21x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 22.58x · Around the industry average

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

38.17x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 18.43x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$27.00 vs. current price +72.7%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 중형주

Who owns it?

Ownership flow is positive

Insider modest net buying +0.1% · Institutional net buying +17.0% · Short interest moderate 9.6% · Short interest up +4.2pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

+0.1%

Insiders little change

🏦 Institutions (funds & investors)

+17.0%

Institutions large net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 48.3%

Moderate institutional participation

Healthcare 중형주 Median 89.4%

🧑‍💼 Insiders 56.7%

Founder/management large holders (strong skin-in-the-game)

Healthcare 중형주 Median 9.4%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

9.6%

Moderate

Healthcare 중형주 Median 11.3%

Past 90 days 📈 +4.2%p increase

Short interest days to cover

3.8 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 282.6M주

Float (tradable shares) 122.3M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding CAI

ETFs with the highest weightings · 10 total shown

IDNA

iShares Genomics Immunology and Healthcare ETF

2.44%

$189M

FMED

Fidelity Disruptive Medicine ETF

1.71%

$46M

EKG

First Trust Nasdaq Lux Digital Health Solutions ETF

1.30%

$4M

GURU

Global X Guru Index ETF

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
CAI This Stock	$4.4B	-	7.4 ▼	28.35% ▲	-	+0.7%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 카리즈라이프사이언스(CAI)?

카리즈라이프사이언스(CAI) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of CAI?

The market cap of CAI is approximately $4.4B, ranking 1,496 within its sector.

What is the 52-week high and low for CAI?

CAI has recorded a 52-week high of $42.50 and a low of $14.19.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.